Skip to main content
SpringerLink
Log in

90K (Mac-2 BP) and galectins in tumor progression and metastasis

  • Published:
Glycoconjugate Journal Aims and scope Submit manuscript

Abstract

Galectins and their ligands have been implicated in cell transformation and cancer metastasis, and found to have prognostic value. Mac-2 BP, also known as 90K, is a highly glycosylated, secreted protein extensively studied in human cancer, which binds galectin-1, galectin-3 and galectin-7. High expression levels of 90K are associated with a shorter survival, the occurrence of metastasis or a reduced response to chemotherapy in patients with different types of malignancy. The mechanisms underlying the prognostic significance of 90K and galectins in cancer are far from being understood, although they may be related to the ability of these proteins to interact and, to some extent, modulate cell-cell and cell-matrix adhesion and apoptosis. The resulting scenario is even more complex, as data have been presented that all these proteins might be associated with either a positive or a negative outcome of the patients. It is hypothesised that different galectins and galectin ligands with overlapping or opposite functions, expressed in different tumors during the different steps of the metastatic cascade might play a crucial role in tumor progression. Published in 2004.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A, Galectin-3: A novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family, Cancer Res 57, 5272-6 (1997).

    Google Scholar 

  2. Kasai K, Hirabayashi J, Galectins: A family of animal lectins that decipher glycocodes. J Biochem 119, 1-8 (1996).

    Google Scholar 

  3. Kim HR, Lin HM, Biliran H, Raz A, Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells, Cancer Res 59, 4148-54 (1999).

    Google Scholar 

  4. Matarrese P, Fusco O, Tinari N, Natoli C, Liu FT, Semeraro ML, Malorni W, Iacobelli S, Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. Int J Cancer 85, 545-54 (2000).

    Google Scholar 

  5. Yang RY, Hsu DK, Liu FT, Expression of galectin-3 modulates T-cell growth and apoptosis, Proc Natl Acad Sci USA 93, 6737-42 (1996).

    Google Scholar 

  6. Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A, Galectin-3: A novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family, Cancer Res 57, 5272-6 (1997).

    Google Scholar 

  7. Matarrese P, Tinari N, Semeraroa ML, Natolib C, Iacobelli S, Malorni W, Galectin-3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis, FEBS Lett 473, 311-5 (2000).

    Google Scholar 

  8. Inohara H, Akahani S, Raz A, Galectin-3 stimulates cell proliferation, Exp Cell Res 245, 294-302 (1998).

    Google Scholar 

  9. Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, Raz A, Galectin-3 induces endothelial cell morphogenesis and angiogenesis, Am J Pathol 156, 899-909 (2000).

    Google Scholar 

  10. Woo HJ, Shaw LM, Messier JM, Mercurio AM, The major nonintegrin laminin binding protein of macrophages is identical to carbohydrate binding protein 35 (Mac-2), J Biol Chem 265, 7097-9 (1990).

    Google Scholar 

  11. Barondes SH, Cooper DN, Gitt MA, Leffler H. Galectins, Structure and function of a large family of animal lectins, J Biol Chem 269, 20807-10 (1994).

    Google Scholar 

  12. Koths K, Taylor E, Halenbeck R, Casipit C, Wang A, Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain, J Biol Chem 268, 14245-9 (1993).

    Google Scholar 

  13. Ullrich A, Sures I, D'Egidio M, Jallal B, Powell TJ, Herbst R, Dreps A, Azam M, Rubinstein M, Natoli C, et al., The secreted tumor-associated antigen 90K is a potent immune stimulator, J Biol Chem 269, 18401-7 (1994).

    Google Scholar 

  14. Iacobelli S, Arno E, D'Orazio A, Coletti G, Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer, Cancer Res 46, 3005-10 (1986).

    Google Scholar 

  15. Tinari N, Kuwabara I, Huflejt ME, Shen PF, Iacobelli S, Liu FT, Glycoprotein 90K/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation, Int J Cancer 91, 167-72 (2001).

    Google Scholar 

  16. Andre S, Pieters RJ, Vrasidas I, Kaltner H, Kuwabara I, Liu FT, Liskamp RM, Gabius HJ, Wedgelike glycodendrimers as inhibitors of binding of mammalian galectins to glycoproteins, lactose maxicluster, and cell surface glycoconjugates, Chembiochem 2, 822-30 (2001).

    Google Scholar 

  17. Resnick D, Pearson A, Krieger M, The SRCR superfamily: A family reminescent of the Ig superfamily, Trends Biochem Sci 19, 5-8 (1994).

    Google Scholar 

  18. Sasaki T, Brakebusch C, Engel J, Timpl R, Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds beta1 integrins, collagens and fibronectin, EMBO J 17, 1606-13 (1998).

    Google Scholar 

  19. D'Ostilio N, Sabatino G, Natoli C, Ullrich A, Iacobelli S, 90K (Mac-2 BP) in human milk, Clin Exp Immunol 104, 543-6 (1996).

    Google Scholar 

  20. Artini M, Natoli C, Tinari N, Costanzo A, Marinelli R, Balsano C, Porcari P, Angelucci D, D'Egidio M, Levrero M, Iacobelli S, Elevated serum levels of 90K/MAC-2BPpredict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients, J Hepatol 25, 212-7 (1996).

    Google Scholar 

  21. Natoli C, Dianzani F, Mazzotta F, Balocchini E, Pierotti P, Antonelli G, Iacobelli S, 90K protein: A new predictor marker of disease progression in human immunodeficiency virus infection, J Acquir Immune Defic Syndr 6, 370-5 (1993).

    Google Scholar 

  22. Briggs NC, Natoli C, Tinari N, D'Egidio M, Goedert JJ, Iacobelli S, A90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men, AIDS Res Hum Retroviruses 9, 811-6 (1993).

    Google Scholar 

  23. Pelliccia P, Natoli C, Petitti MT, Verrotti A, Chiarelli F, Iacobelli S, Elevated levels of circulating immunostimulatory 90K in Henoch-Schoenlein purpura, J Clin Immunol 19, 143-7 (1999).

    Google Scholar 

  24. Iacobelli S, Arno E, Sismondi P, Natoli C, Gentiloni N, Scambia G, Giai M, Cortese P, Panici PB, Mancuso S, Measurement of a breast cancer associated antigen detected by monoclonal antibody SP-2 in sera of cancer patients, Breast Cancer Res Treat 11, 19-30 (1988).

    Google Scholar 

  25. Scambia G, Panici PB, Baiocchi G, Perrone L, Iacobelli S, Mancuso S, Measurement of a monoclonal-antibody-defined antigen (90K) in the sera of patients with ovarian cancer, Anticancer Res 8, 761-4 (1988).

    Google Scholar 

  26. Natoli C, Garufi C, Tinari N, D'Egidio M, Lesti G, Gaspari LA, Visini R, Iacobelli S, Dynamic test with recombinant interferonalpha-2b: Effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease, Br J Cancer 67, 564-7 (1993).

    Google Scholar 

  27. Iacobelli S, Sismondi P, Giai M, D'Egidio M, Tinari N, Amatetti C, Di Stefano P, Natoli C, Prognostic value of a novel circulating serum 90K antigen in breast cancer, Br J Cancer 69, 172-6 (1994).

    Google Scholar 

  28. Rea A, Calmieri G, Tinari N, Natoli C, Tagliaferro P, Morabito A, Grassadonia A, Bianco AR, Iacobelli S, 90K is a serum marker of poor prognosis in non-Hodgikin's lymphoma patients, Oncol Rep 1, 723-5 (1994).

    Google Scholar 

  29. Zeimet AG, Natoli C, Herold M, Fuchs D, Windbichler G, Daxenbichler G, Iacobelli S, Dapunt O, Marth C, Circulating immunostimulatory protein 90K and soluble interleukin-2-receptor in human ovarian cancer, Int J Cancer 68, 34-8 (1996).

    Google Scholar 

  30. Marchetti A, Tinari N, Buttitta F, Chella A, Angeletti CA, Sacco R, Mucilli F, Ullrich A, Iacobelli S, Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients, Cancer Res 62, 2535-9 (2002).

    Google Scholar 

  31. Fornarini B, D'Ambrosio C, Natoli C, Tinari N, Silingardi V, Iacobelli S, Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo, Blood 96, 3282-5 (2000).

    Google Scholar 

  32. Zhang DS, Jiang WQ, Li S, Zhang XS, Mao H, Chen XQ, Li YH, Zhan J, Wang FH, Predictive significance of serum 90K/Mac-2BP on chemotherapy response in non-Hodgkin's lymphoma, Ai Zheng 22, 870-3 (2003).

    Google Scholar 

  33. Raz A, Lotan R, Endogenous galactoside-binding lectins: A new class of functional tumor cell surface molecules related to metastasis, Cancer Metastasis Rev 6, 433-52 (1987).

    Google Scholar 

  34. Raz A, Lotan R, Lectin-like activities associated with human and murine neoplastic cells, Cancer Res 41, 3642-7 (1981).

    Google Scholar 

  35. Raz A, Zhu DG, Hogan V, Shah N, Raz T, Karkash R, Pazerini G, Carmi P, Evidence for the role of 34-kDa galactoside-binding lectin in transformation and metastasis, Int J Cancer 46, 871-7 (1990).

    Google Scholar 

  36. Bresalier RS, Mazurek N, Sternberg LR, Byrd JC, Yunker CK, Nangia-Makker P, Raz A, Metastasis of human colon cancer is altered by modifying expression of the beta-galactoside-binding protein galectin 3, Gastroenterology 115, 287-96 (1998).

    Google Scholar 

  37. Inufusa H, Nakamura M, Adachi T, Aga M, Kurimoto M, Nakatani Y, Wakano T, Miyake M, Okuno K, Shiozaki H, Yasutomi M, Role of galectin-3 in adenocarcinoma liver metastasis, Int J Oncol 19, 913-9 (2001).

    Google Scholar 

  38. Song YK, Billiar TR, Lee YJ, Role of galectin-3 in breast cancer metastasis: Involvement of nitric oxide, Am J Pathol 160, 1069-75 (2002).

    Google Scholar 

  39. Honjo Y, Nangia-Makker P, Inohara H, Raz A, Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells, Clin Cancer Res 7, 661-8 (2001).

    Google Scholar 

  40. Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E, Iacobelli S, Concentrations of galectin-3 in the sera of normal controls and cancer patients, Clin Cancer Res 6, 1389-93 (2000).

    Google Scholar 

  41. Xu XC, el-Naggar AK, Lotan R, Differential expression of galectin-1 and galectin-3 in thyroid tumors: Potential diagnostic implications, Am J Pathol 147, 815-22 (1995).

    Google Scholar 

  42. Chiariotti L, Berlingieri MT, Battaglia C, Benvenuto G, Martelli ML, Salvatore P, Chiappetta G, Bruni CB, Fusco A, Expression of galectin-1 in normal human thyroid gland and in differentiated and poorly differentiated thyroid tumors, Int J Cancer 64, 171-5 (1995).

    Google Scholar 

  43. Camby I, Belot N, Rorive S, Lefranc F, Maurage CA, Lahm H, Kaltner H, Hadari Y, Ruchoux MM, Brotchi J, Zick Y, Salmon I, Gabius HJ, Kiss R, Galectins are differentially expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration, Brain Pathol 11, 12-26 (2001).

    Google Scholar 

  44. Lotan R, Ito H, Yasui W, Yokozaki H, Lotan D, Tahara E, Expression of a 31-kDa lactoside-binding lectin in normal human gastric mucosa and in primary and metastatic gastric carcinomas, Int J Cancer 56, 474-80 (1994).

    Google Scholar 

  45. Schoeppner HL, Raz A, Ho SB, Bresalier RS, Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon, Cancer 75, 2818-26 (1995).

    Google Scholar 

  46. Sanjuan X, Fernandez PL, Castells A, Castronovo V, van den Brule F, Liu FT, Cardesa A, Campo E, Differential expression of galectin 3 and galectin 1 in colorectal cancer progression, Gastroenterology 113, 1906-15 (1997).

    Google Scholar 

  47. Schaffert C, Pour PM, Chaney WG, Localization of galectin-3 in normal and diseased pancreatic tissue, Int J Pancreatol 23, 1-9 (1998).

    Google Scholar 

  48. Berberat_ PO, Friess H, Wang L, Zhu Z, Bley T, Frigeri L, Zimmermann A, Buchler MW, Comparative analysis of galectins in primary tumors and tumor metastasis in human pancreatic cancer, J Histochem Cytochem 49, 539-49 (2001).

    Google Scholar 

  49. Hsu DK, Dowling CA, Jeng KC, Chen JT, Yang RY, Liu FT, Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma, Int J Cancer 81, 519-26 (1999).

    Google Scholar 

  50. Inohara H, Akahani S, Koths K, Raz A, Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion, Cancer Res 56(19), 4530-4 (1996).

    Google Scholar 

  51. Sato S, Hughes RC, Binding specificity of a baby hamster kidney lectin for H type I and II chains, polylactosamine glycans, and appropriately glycosylated forms of laminin and fibronectin, J Biol Chem 267, 6983-90 (1992).

    Google Scholar 

  52. Jallal B, Powell J, Zachwieja J, Brakebusch C, Germain L, Jacobs J, Iacobelli S, Ullrich A, Suppression of tumor growth in vivo by local and systemic 90K level increase, Cancer Res 55, 3223-7 (1995).

    Google Scholar 

  53. Ellerhorst J, Troncoso P, Xu XC, Lee J, Lotan R, Galectin-1 and galectin-3 expression in human prostate tissue and prostate cancer, Urol Res 27, 362-7 (1999).

    Google Scholar 

  54. Castronovo V, Van Den Brule FA, Jackers P, Clausse N, Liu FT, Gillet C, Sobel ME, Decreased expression of galectin-3 is associated with progression of human breast cancer, J Pathol 179, 43-8 (1996).

    Google Scholar 

  55. Idikio H, Galectin-3 expression in human breast carcinoma: Correlation with cancer histologic grade, Int J Oncol 12, 1287-90 (1998).

    Google Scholar 

  56. van den Brule FA, Buicu C, Berchuck A, Bast RC, Deprez M, Liu FT, Cooper DN, Pieters C, Sobel ME, Castronovo V, Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma, Hum Pathol 27, 1185-91 (1996).

    Google Scholar 

  57. Castronovo V, Campo E, van den Brule FA, Claysmith AP, Cioce V, Liu FT, Fernandez PL, Sobel ME, Inverse modulation of steadystate messenger RNA levels of two non-integrin laminin-binding proteins in human colon carcinoma, J Natl Cancer Inst 84, 1161-9 (1992).

    Google Scholar 

  58. Lotz MM, Andrews CW, Jr, Korzelius CA, Lee EC, Steele GD, Jr, Clarke A, Mercurio AM, Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma, Proc Natl Acad Sci USA 90, 3466-70 (1993).

    Google Scholar 

  59. Choufani G, Nagy N, Saussez S, Marchant H, Bisschop P, Burchert M, Danguy A, Louryan S, Salmon I, Gabius HJ, Kiss R, Hassid S, The levels of expression of galectin-1, galectin-3, and the Thomsen-Friedenreich antigen and their binding sites decrease as clinical aggressiveness increases in head and neck cancers, Cancer 86, 2353-63 (1999).

    Google Scholar 

  60. Lahm H, Andre S, Hoeflich A, Fischer JR, Sordat B, Kaltner H, Wolf E, Gabius HJ, Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures, J Cancer Res Clin Oncol 127, 375-86 (2001).

    Google Scholar 

  61. Piantelli M, Iacobelli S, Almadori G, Iezzi M, Tinari N, Natoli C, Cadoni G, Lauriola L, Ranelletti F, Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma, J Clin Oncol 20, 3850-6 (2002).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology and Neurosciences, Sections of Medical Oncology and Pathology, University “G. D'Annunzio”, Chieti, 66100, Italy

    Antonino Grassadonia, Nicola Tinari, Ida Iurisci, Enza Piccolo, Alba Cumashi, Pasquale Innominato, Maurizia D'Egidio, Clara Natoli, Mauro Piantelli & Stefano Iacobelli

Authors
  1. Antonino Grassadonia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicola Tinari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ida Iurisci
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Enza Piccolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alba Cumashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Pasquale Innominato
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Maurizia D'Egidio
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Clara Natoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mauro Piantelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Stefano Iacobelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefano Iacobelli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grassadonia, A., Tinari, N., Iurisci, I. et al. 90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconj J 19, 551–556 (2002). https://doi.org/10.1023/B:GLYC.0000014085.00706.d4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:GLYC.0000014085.00706.d4

Search

Navigation